Abstract
The multidrug resistance (MDR) phenotype exhibited by cancer cells is believed to be hampering successful chemotherapy treatment in cancer patients. A group of ABC drug transporters which particularly include P-glycoprotein (Pgp) contribute to this phenotype. Thus, there is a need to anticipate whether drug candidates are possible Pgp substrates or noncompetitive inhibitors. Therefore, a pharmacophore model was created based on known Pgp inhibitors and it was used to screen a database of commercial compounds. After the screening, twenty-one candidate compounds were selected and their influence in the intracellular accumulation of Pgp substrate Rhodamine-123 (Rh123) was investigated by flow cytometry. Eleven compounds were found to significantly increase the accumulation of Rh123, four were found to decrease and six showed only a slight effect on the accumulation of Rh123. Furthermore, the competitive/non-competitive mechanism for the most promising compounds was determined by a luminescence Pgp’s ATPase assay. Based on the cytometry results, a new pharmacophore was created for the Pgp inhibitory activity. The overall results provide important clues on how to proceed towards the discovery of Pgp inhibitors and which type of molecules merit further analysis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dongping, M.: Identify P-glycoprotein Substrates and Inhibitors with the Rapid, HTS Pgp-GloTM Assay System (2007), http://www.promega.com/pnotes/96/15080_11/15080_11.pdf (Accessed February 12, 2010)
Goda, K., Bacso, Z., et al.: Multidrug resistance through the spectacle of P-glycoprotein. Curr. Cancer Drug Targets 9, 281–297 (2009)
Guner, O., Clement, O., et al.: Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr. Med. Chem. 11, 2991–3005 (2004)
Higgins, C.F.: Multiple molecular mechanisms for multidrug resistance transporters. Nature 446, 749–757 (2007)
Lehne, G.: P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets 1, 85–99 (2000)
Lima, R.T., Guimarães, J.E., et al.: Overcoming K562Dox resistance to STI571 (Gleevec) by downregulation of P-gp expression using siRNAs. Cancer Ther. 5, 67–76 (2007)
Lipinski, C.A.: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44, 235–249 (2000)
Matsunaga, T., Kose, E., et al.: Determination of p-glycoprotein ATPase activity using luciferase. Biol. Pharm. Bull. 29, 560–564 (2006)
Pajeva, I.K., Globisch, C., et al.: Structure-function relationships of multidrug resistance P-glycoprotein. J. Med. Chem. 47, 2523–2533 (2004)
Schneidman-Duhovny, D., Dror, O., et al.: PharmaGist: a webserver for ligand-based pharmacophore detection. Nucleic Acids Res. 228, W223–W228 (2008)
Wishart, D.S., Knox, C., et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 672, D668–D672 (2006)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Palmeira, A., Rodrigues, F., Sousa, E., Pinto, M., Vasconcelos, M.H., Fernandes, M.X. (2010). Pharmacophore-Based Screening as a Clue for the Discovery of New P-Glycoprotein Inhibitors. In: Rocha, M.P., Riverola, F.F., Shatkay, H., Corchado, J.M. (eds) Advances in Bioinformatics. Advances in Intelligent and Soft Computing, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13214-8_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-13214-8_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13213-1
Online ISBN: 978-3-642-13214-8
eBook Packages: EngineeringEngineering (R0)